Pipeline
Hemoglobinopathies
-
Exa-cel: β-thalassemia
Partner: Vertex
Structure: Collaboration
-
Exa-cel: Sickle cell disease (SCD)
Partner: Vertex
Structure: Collaboration
-
Next-generation conditioning
Structure: Wholly-owned
-
In vivo editing of HSCs
Structure: Wholly-owned
Immuno-Oncology
-
CTX110
Description: CTX110 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the treatment of CD19+ malignancies
Structure: Wholly-owned
For more information on CTX110 please click here
-
CTX112
Structure: Wholly-owned
-
CTX130
Description: CTX130 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD70 in development for the treatment of both solid tumors and hematologic malignancies
Structure: Wholly-owned
For more information on CTX130 please click here
-
CTX131
Structure: Wholly-owned
-
Anti-CD70 allogeneic CAR-NK
Partner: Nkarta Therapeutics
Structure: Collaboration
-
CTX121: Anti-BCMA allogeneic CAR-T
Structure: Wholly-owned
-
Anti-CD83 autologous CAR-T
Partner: Moffitt Cancer Center
Structure: Collaboration
-
Anti-GPC3 autologous CAR-T
Partner: Roswell Park Comprehensive Cancer Center
Structure: Collaboration
Regenerative Medicine
-
VCTX210: Type I diabetes mellitus
Description: Allogeneic beta-cell replacement therapy derived from a CRISPR/Cas9 gene-edited immune-evasive stem cell line in development for the treatment of diabetes
Partner: ViaCyte
Structure: Collaboration
-
VCTX211: Type I diabetes mellitus
Partner: ViaCyte
Structure: Collaboration
-
VCTX212: Type I/II diabetes mellitus
Partner: ViaCyte
Structure: Collaboration
In Vivo Approaches
-
CTX310: ANGPTL3
Structure: Wholly-owned
-
CTX320: Lp(a)
Structure: Wholly-owned
-
CTX330: PCSK9
Structure: Wholly-owned
-
Hemophilia A
Partner: Bayer
Structure: Collaboration
-
Undisclosed deletion and insertion programs
Structure: Various
-
Friedreich's ataxia (FA)
Partner: Capsida Biotherapeutics
Structure: Collaboration
-
Amyotrophic lateral sclerosis (ALS)
Partner: Capsida Biotherapeutics
Structure: Collaboration
Tackling a range of diseases with different approaches
We have established a portfolio of programs by selecting disease targets based on a number of criteria, including unmet medical need, technical feasibility, advantages of CRISPR/Cas9 relative to other approaches and time required to advance the product candidate into and through clinical trials.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.